Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

Phase 2

Completed

Conditions: Lymphoma

Interventions: Biological: bevacizumab
Drug: cyclophosphamide
Drug: doxorubicin
Drug: prednisone
Drug: vincristine

First Posted Date: 2005-09-22

Last Posted Date: 2023-06-18

Lead Sponsor: Eastern Cooperative Oncology Group

Target Recruit Count: 46

Registration Number: NCT00217425

Locations: 🇺🇸
Green Bay Oncology, Limited - Oconto Falls, Oconto Falls, Wisconsin, United States
🇺🇸
Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States
🇺🇸
California Cancer Care, Incorporated - Greenbrae, Greenbrae, California, United States

and more 107 locations

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

Phase 2

Completed

Conditions: Lymphoma

First Posted Date: 2005-09-22

Last Posted Date: 2013-06-20

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT00217503

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL

Phase 3

Conditions: Lymphoma, Mantle-Cell

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: BCNU
Drug: Cisplatinum
Drug: Melphalan
Drug: Ara-C
Drug: Etoposide
Drug: Dexamethasone
Drug: G-CSF
Procedure: stem cell harvest
Procedure: total body irradiation

First Posted Date: 2005-09-21

Last Posted Date: 2012-09-10

Lead Sponsor: European Mantle Cell Lymphoma Network

Target Recruit Count: 360

Registration Number: NCT00209222

Locations: 🇫🇷
Groupe D´Etudes des Lymphomes De l´Adulte (GELA), Paris, France
🇩🇪
German Low Grade Study Group (Glsg), Munich, Germany
🇵🇱
The Maria Sklodowska Memorial, Cancer Center - Inst. of Oncology, Warszawa, Poland

Zoledronic Acid (ZOMETA) With Cyclophosphamide With Neuroblastoma and Cortical Bone Involvement

Phase 1

Completed

Conditions: NEUROBLASTOMA

Interventions: Drug: Zolendric acid
Drug: Cyclophosphamide

First Posted Date: 2005-09-21

Last Posted Date: 2013-08-02

Lead Sponsor: Baylor College of Medicine

Target Recruit Count: 21

Registration Number: NCT00206388

Locations: 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Indiana University-Riley Children's Hospital, Indianapolis, Indiana, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States

and more 5 locations

A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Phase 2

Completed

Conditions: Lymphoma, T-Cell, Peripheral

Interventions: Drug: Denileukin diftitox
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Other: Pegfilgrastim

First Posted Date: 2005-09-21

Last Posted Date: 2020-03-18

Lead Sponsor: Eisai Inc.

Target Recruit Count: 49

Registration Number: NCT00211185

Locations: 🇺🇸
Hematology Oncology Associates of IL, Chicago, Illinois, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 44 locations

Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL

Phase 3

Conditions: Lymphoma, Mantle-Cell

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Fludarabine
Procedure: Rituximab maintenance
Drug: Vincristine
Drug: Prednisone
Drug: Interferon-alpha
Drug: pegylated formula Interferon-alpha 2b
Procedure: Interferon maintenance

First Posted Date: 2005-09-21

Last Posted Date: 2017-03-07

Lead Sponsor: European Mantle Cell Lymphoma Network

Target Recruit Count: 570

Registration Number: NCT00209209

Locations: 🇳🇱
HOVON - Dutch Haemato-Oncology Association (HOVON-Datacenter), Rotterdam, Netherlands
🇩🇰
Nordic Lymphoma Group, Copenhagen, Denmark
🇩🇪
German Low Grade Study Group (Glsg), Munich, Germany

and more 4 locations